Development and benchmarking of a Deep Learning-based MRI-guided gross tumor segmentation algorithm for Radiomics analyses in extremity soft tissue sarcomas.

Deep Learning MRI Radiology Radiomics Radiotherapy Soft tissue sarcoma Tumor Volume

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
21 May 2024
Historique:
received: 30 07 2023
revised: 05 05 2024
accepted: 10 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 23 5 2024
Statut: aheadofprint

Résumé

Volume of interest (VOI) segmentation is a crucial step for Radiomics analyses and radiotherapy (RT) treatment planning. Because it can be time-consuming and subject to inter-observer variability, we developed and tested a Deep Learning-based automatic segmentation (DLBAS) algorithm to reproducibly predict the primary gross tumor as VOI for Radiomics analyses in extremity soft tissue sarcomas (STS). A DLBAS algorithm was trained on a cohort of 157 patients and externally tested on an independent cohort of 87 patients using contrast-enhanced MRI. Manual tumor delineations by a radiation oncologist served as ground truths (GTs). A benchmark study with 20 cases from the test cohort compared the DLBAS predictions against manual VOI segmentations of two residents (ERs) and clinical delineations of two radiation oncologists (ROs). The ROs rated DLBAS predictions regarding their direct applicability. The DLBAS achieved a median dice similarity coefficient (DSC) of 0.88 against the GTs in the entire test cohort (interquartile range (IQR): 0.11) and a median DSC of 0.89 (IQR 0.07) and 0.82 (IQR 0.10) in comparison to ERs and ROs, respectively. Radiomics feature stability was high with a median intraclass correlation coefficient of 0.97, 0.95 and 0.94 for GTs, ERs, and ROs, respectively. DLBAS predictions were deemed clinically suitable by the two ROs in 35% and 20% of cases, respectively. The results demonstrate that the DLBAS algorithm provides reproducible VOI predictions for radiomics feature extraction. Variability remains regarding direct clinical applicability of predictions for RT treatment planning.

Sections du résumé

BACKGROUND BACKGROUND
Volume of interest (VOI) segmentation is a crucial step for Radiomics analyses and radiotherapy (RT) treatment planning. Because it can be time-consuming and subject to inter-observer variability, we developed and tested a Deep Learning-based automatic segmentation (DLBAS) algorithm to reproducibly predict the primary gross tumor as VOI for Radiomics analyses in extremity soft tissue sarcomas (STS).
METHODS METHODS
A DLBAS algorithm was trained on a cohort of 157 patients and externally tested on an independent cohort of 87 patients using contrast-enhanced MRI. Manual tumor delineations by a radiation oncologist served as ground truths (GTs). A benchmark study with 20 cases from the test cohort compared the DLBAS predictions against manual VOI segmentations of two residents (ERs) and clinical delineations of two radiation oncologists (ROs). The ROs rated DLBAS predictions regarding their direct applicability.
RESULTS RESULTS
The DLBAS achieved a median dice similarity coefficient (DSC) of 0.88 against the GTs in the entire test cohort (interquartile range (IQR): 0.11) and a median DSC of 0.89 (IQR 0.07) and 0.82 (IQR 0.10) in comparison to ERs and ROs, respectively. Radiomics feature stability was high with a median intraclass correlation coefficient of 0.97, 0.95 and 0.94 for GTs, ERs, and ROs, respectively. DLBAS predictions were deemed clinically suitable by the two ROs in 35% and 20% of cases, respectively.
CONCLUSION CONCLUSIONS
The results demonstrate that the DLBAS algorithm provides reproducible VOI predictions for radiomics feature extraction. Variability remains regarding direct clinical applicability of predictions for RT treatment planning.

Identifiants

pubmed: 38782301
pii: S0167-8140(24)00608-X
doi: 10.1016/j.radonc.2024.110338
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110338

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jan C Peeken (JC)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMGU), German Research Center for Environmental Health GmbH, Neuherberg, Germany; Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands.

Lucas Etzel (L)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany. Electronic address: lucas.etzel@tum.de.

Tim Tomov (T)

Department of Informatics, Technical University of Munich (TUM), Garching, Germany.

Stefan Münch (S)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Lars Schüttrumpf (L)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Julius H Shaktour (JH)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Johannes Kiechle (J)

Department of Informatics, Technical University of Munich (TUM), Garching, Germany.

Carolin Knebel (C)

Department of Orthopaedics and Sports Orthopaedics, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Stephanie K Schaub (SK)

Department of Radiation Oncology, University of Washington, Seattle, USA.

Nina A Mayr (NA)

College of Human Medicine, Michigan State University, East Lansing, MI, USA.

Henry C Woodruff (HC)

Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands; Department of Radiology and Nuclear Imaging, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands.

Philippe Lambin (P)

Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands; Department of Radiology and Nuclear Imaging, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, the Netherlands.

Alexandra S Gersing (AS)

Institute of Neuroradiology, LMU Klinikum, LMU Munich, Munich, Germany.

Denise Bernhardt (D)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.

Matthew J Nyflot (MJ)

Department of Radiation Oncology, University of Washington, Seattle, USA; Department of Radiology, University of Washington, Seattle, USA.

Bjoern Menze (B)

Department of Informatics, Technical University of Munich (TUM), Garching, Germany.

Stephanie E Combs (SE)

Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany; Institute of Radiation Medicine (IRM), Helmholtz Zentrum München (HMGU), German Research Center for Environmental Health GmbH, Neuherberg, Germany.

Fernando Navarro (F)

Department of Informatics, Technical University of Munich (TUM), Garching, Germany.

Classifications MeSH